Nuclera
Nuclera develops automated benchtop platforms and integrated systems for rapid protein expression, optimization, and purification, utilizing cell-free synthesis, digital microfluidics, and software-driven workflows. Their technology enables miniaturized and scalable protein prototyping—including challenging targets such as membrane proteins—directly at the lab bench. Nuclera serves academic and industrial researchers, focusing on reducing turnaround time for functional protein access and streamlining screening and production. The company has secured significant funding to enable broad commercialization, expanded their leadership team to support scale-up, and continues to drive advancements in drug discovery, proteomics, and experimental automation.
Nuclera
1000 Technology Park Dr, Suite B, Billerica, MA 01821
Patents
Microfluidic devices containing reversibly pinned droplet samples and methods
2025-07-29 • US-12370550-B2
View DetailsMethod for reagent-specific driving EWoD arrays in microfluidic systems
2024-12-31 • US-12179203-B2
View DetailsWhat We Do
Integrated benchtop system for cell-free protein synthesis, digital microfluidics, and software-driven automation to accelerate the design, screening, and purification of proteins, including membrane proteins.
Provision of rapid, high-throughput protein expression and purification services through contract research organizations utilizing automated benchtop systems.
Biologics
Diagnostics
Drugs
Key People
Chief Executive Officer and Co-founder
Chairman of the Board
Chief Financial Officer
Chief Commercial Officer
Associate Vice President, Marketing
Scientific Advisor
Scientific Advisor
Scientific Advisor
RT Partners Observer
Scientific Advisor
Chief Operating Officer and Co-founder
Senior Vice President, Product Development
Senior Vice President of People
Non-Executive Director
Board Member
Board Member
Board Member
News & Updates
Received Innovate UK grants supporting advanced platform development, including for fast protein prototyping and engineering biology.
Ranked among the fastest-growing startups in the UK and Ireland for 2024.
Certified for cybersecurity practices by the UK government standard.
Recognized as one of the UK's most exciting growth-stage technology companies by Tech Nation.
Created new headquarters at One Vision Park to support operational growth and the commercial launch of protein prototyping technology.
Secured $75 million to accelerate commercial rollout of benchtop protein screening and production technology.